A US jury has hit two drug companies with a record $9bn fine for hiding an alleged link between a best-selling diabetes medicine and bladder cancer.
The Louisiana jury imposed the penalty on Takeda, Japan’s biggest drugmaker and Eli Lilly, its former US partner, in the first federal trial over the controversial Actos medicine.
The ruling adds to a history of big penalties for pharmaceutical groups accused of concealing the health risks of new drugs, and promises to increase pressure on the industry to open clinical trial data to greater transparency.
您已閱讀33%（554字），剩余67%（1104字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。